Preferred reflexive panel for diagnosing myasthenia gravis. Includes acetylcholine receptor (AChR) binding and blocking antibodies with reflex to AChR modulating antibodies.
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Component
Interpretation
Acetylcholine Receptor Binding Antibody
Negative: Positive:
0.0-0.4 nmol/L 0.5 nmol/L or greater
Acetylcholine Receptor Blocking Antibody
Negative: Indeterminate: Positive:
0-26% blocking 27-41% blocking 42% or greater blocking
Ordering
Ordering Recommendations
Preferred reflexive panel for diagnosing myasthenia gravis. Includes acetylcholine receptor (AChR) binding and blocking antibodies with reflex to AChR modulating antibodies.
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Component
Interpretation
Acetylcholine Receptor Binding Antibody
Negative: Positive:
0.0-0.4 nmol/L 0.5 nmol/L or greater
Acetylcholine Receptor Blocking Antibody
Negative: Indeterminate: Positive:
0-26% blocking 27-41% blocking 42% or greater blocking
